[EFFECT] Cellectar Biosciences INC NEW SEC Filing

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

EFFECT

07/02/2025 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	July 1, 2025 9:00 A.M.

Form:

S-1

CIK:	0001279704
Company Name:	Cellectar Biosciences, Inc.
File Number:	333-288333

Source: View Original Filing on SEC EDGAR

Cellectar Biosciences Inc

NASDAQ:CLRB

CLRB Rankings

#6338 Ranked by Market Cap

N/A Ranked by Dividends

CLRB Latest News

Mar 4, 2026

Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates

Feb 25, 2026

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026

Feb 17, 2026

Cellectar Biosciences Expands Global Intellectual Property Estate

Jan 9, 2026

Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference

Dec 16, 2025

Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies

CLRB Latest SEC Filings

Mar 4, 2026

[8-K] Cellectar Biosciences, Inc. Reports Material Event

Mar 4, 2026

[10-K] Cellectar Biosciences, Inc. Files Annual Report

Feb 13, 2026

[SCHEDULE 13G/A] Cellectar Biosciences, Inc. Amended Passive Investment Disclosure

Feb 10, 2026

[SCHEDULE 13G/A] Cellectar Biosciences, Inc. Amended Passive Investment Disclosure

Feb 4, 2026

[SCHEDULE 13G/A] Cellectar Biosciences, Inc. Amended Passive Investment Disclosure

CLRB Stock Data

Market Cap 11.75M

Float 4.07M

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City FLORHAM PARK